All In Biotech

Drug Trial Radar · NCT04819776

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iloperidone for 4 Weeks in the Treatment of Patients With Acute Manic Episodes Associated With Bipolar I Disorder

Last checked: Nov 20, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 417 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

417

Actual

Start

Mar 22, 2021

Primary completion

Sep 7, 2022

Study completion Aug 16, 2023

Sponsor

Lead sponsor
Vanda PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.

Conditions

  • Bipolar I Disorder

Interventions

  • IloperidoneDrug

    Oral iloperidone

  • Iloperidone PlaceboDrug

    Oral placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total ScoreTime frame: Week 4

Locations

27 sites in 3 countries. Site status is shown where the registry gives one.

  • Vanda Investigational Site

    Little Rock, Arkansas

  • Vanda Investigational Site

    Rogers, Arkansas

  • Vanda Investigational Site

    Cerritos, California

  • Vanda Investigational Site

    Culver City, California

  • Vanda Investigational Site

    Long Beach, California

  • Vanda Investigational Site

    Orange, California

  • Vanda Investigational Site

    Torrance, California

  • Vanda Investigational Site

    Miami Lakes, Florida

  • Vanda Investigational Site

    Oakland Park, Florida

  • Vanda Investigational Site

    Atlanta, Georgia

  • Vanda Investigational Site

    Decatur, Georgia

  • Vanda Investigational Site

    Gaithersburg, Maryland

  • Vanda Investigational Site

    Flowood, Mississippi

  • Vanda Investigational Site

    Las Vegas, Nevada

  • Vanda Investigational Site

    Marlton, New Jersey

  • Vanda Investigational Site

    Dayton, Ohio

  • Vanda Investigational Site

    North Canton, Ohio

  • Vanda Investigational Site

    Austin, Texas

  • Vanda Investigational Site

    DeSoto, Texas

  • Vanda Investigational Site

    Richardson, Texas

  • Vanda Investigational Site

    Kardzhali, Bulgaria

  • Vanda Investigational Site

    Lovech, Bulgaria

  • Vanda Investigational Site

    Veliko Tarnovo, Bulgaria

  • Vanda Investigational Site

    Vratsa, Bulgaria

  • Vanda Investigational Site

    Novi Iskar, Sofia-Grad, Bulgaria

  • Vanda Investigational Site

    Tserova Koria, Veliko Tarnovo, Bulgaria

  • Vanda Investigational Site

    Tuszyn, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.